

#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

## Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul><li>Company</li><li>Novartis Pharmaceuticals</li></ul>	General  All Wales Therapeutics and Toxicology
(remibrutinib)	Centre
Patient/carer groups  • Allergy UK	<ul> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> </ul>
<ul><li>South Asian Health Foundation</li><li>Specialised Healthcare Alliance</li></ul>	<ul><li>British National Formulary</li><li>Care Quality Commission</li></ul>
Healthcare professional groups	Department of Health - Northern Ireland
British Association of Dermatologists	<ul> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products</li> </ul>
<ul><li>British Dermatological Nursing Group</li><li>British Geriatrics Society</li></ul>	Regulatory Agency  National Association of Primary Care
<ul> <li>British Society for Allergy &amp; Clinical Immunology</li> </ul>	<ul><li>National Pharmacy Association</li><li>NHS Confederation</li></ul>
<ul><li>British Society for Immunology</li><li>Primary Care Dermatology Society</li></ul>	NHS Wales Joint Commissioning Group
Royal College of General Practitioners	<ul><li>Scottish Medicines Consortium</li><li>Welsh Government</li></ul>
<ul><li>Royal College of Nursing</li><li>Royal College of Pathologists</li></ul>	Possible comparator companies
<ul><li>Royal College of Physicians</li><li>Royal Pharmaceutical Society</li></ul>	<ul><li>Advanz Pharma (methotrexate)</li><li>Amarox (montelukast)</li></ul>
Royal Society of Medicine	Astellas Pharma (tacrolimus)
UK Clinical Pharmacy Association	<ul> <li>Aurobindo Pharma – Milpharm (montelukast)</li> </ul>
<ul><li>Others</li><li>Department of Health and Social Care</li></ul>	<ul><li>The Boots Company (ranitidine)</li><li>Celltrion Healthcare UK (omalizumab)</li></ul>
NHS England	<ul><li>Cipla EU (methotrexate)</li><li>Chiesi (tacrolimus)</li></ul>
	Dexcel Pharma (ciclosporin)
	<ul><li>Dr Reddy's Laboratories (montelukast)</li><li>Hospira (methotrexate)</li></ul>
	<ul> <li>Glenmark Pharmaceuticals (montelukast)</li> </ul>
	Krka (montelukast)

Provisional stakeholder list for the evaluation of remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356 Issue date: July 2025




Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	<ul> <li>Leo Laboratories (tacrolimus)</li> <li>Medac Pharma (methotrexate)</li> <li>Medley Pharma (cimetidine)</li> <li>Morningside Healthcare (methotrexate)</li> <li>Mylan (nizatidine, ciclosporin)</li> <li>Nordic Pharma (methotrexate)</li> <li>Novartis Pharmaceuticals (ciclosporin, omalizumab)</li> <li>Organon Pharma (montelukast)</li> <li>Orion Pharma (methotrexate)</li> <li>Ranbaxy (UK) a Sun Pharmaceutical Company (ciclosporin, montelukast)</li> <li>Reckitt Benckiser Healthcare (ranitidine)</li> <li>Rivopharm (montelukast)</li> <li>Roche Products (mycophenolate mofetil)</li> <li>Rosemont Pharmaceuticals (cimetidine, methotrexate, mycophenolate mofetil)</li> <li>Sandoz (methotrexate, montelukast, tacrolimus)</li> <li>Santen (ciclosporin)</li> <li>Teva Pharma B.V. (mycophenolate mofetil)</li> <li>Tillomed Laboratories (mycophenolate mofetil)</li> </ul>
	Relevant research groups  British Skin Foundation  Cochrane Skin Group  Genomics England  MRC Clinical Trials Unit  National Institute for Health Research  Associated Public Health groups  Public Health Wales  UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Provisional stakeholder list for the evaluation of remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356 Issue date: July 2025



Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.